New scan may reveal who will benefit from immunotherapy
NCT ID NCT03564197
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether a new type of PET scan, which looks for a protein called PD-L1 on cancer cells, can predict how well patients with advanced lung cancer will respond to the immunotherapy drug nivolumab. Eighty patients received the scan before starting treatment. Researchers then tracked how long their cancer was controlled. The goal is to see if this imaging tool can help personalize treatment decisions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
18F-PD-L1 PET/CT scan (imaging tracer)
What this could lead to
If successful, this scan could help doctors identify which lung cancer patients are most likely to respond to immunotherapy, avoiding ineffective treatments.
What could go wrong
This is an early imaging study, not a treatment trial. The scan's accuracy may not be high enough to change clinical practice, and results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC STAGE IV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Antoni van Leeuwenhoek
Amsterdam, 1060CX, Netherlands
-
Antonius Ziekenhuis
Utrecht, Netherlands
-
Deventer Ziekenhuis
Deventer, Netherlands
-
Jeroen Bosch Ziekenhuis
's-Hertogenbosch, Netherlands
-
LUMC
Leiden, Netherlands
-
MeanderMC
Amersfoort, Netherlands
-
Medisch Centrum Haaglanden
The Hague, Netherlands
-
VUmc
Amsterdam, 1007 MB, Netherlands